Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • CDSCO approves Zydus,...

    CDSCO approves Zydus, SIFI pact to launch Intraocular Lenses in India

    Farhat NasimWritten by Farhat Nasim Published On 2019-04-30T10:15:06+05:30  |  Updated On 16 Aug 2021 1:55 PM IST

    "SIFI's innovative IOLs (Intraocular lenses) have been approved by the Indian Central Drugs Standards Control Organisation(CDSCO) (Directorate General of Health Services) and Ministry of Health & Family Welfare (Medical Device and Diagnostic Division)," Zydus Cadila said in a regulatory filing.


    New Delhi: Drug firm Zydus Cadila Tuesday said that the company has tied up with Italian ophthalmic company, SIFI to market innovative IOLs (Intraocular lenses) and surgical products developed in Italy and licensed in India by SIFI.


    "SIFI's innovative IOLs (Intraocular lenses) have been approved by the Indian Central Drugs Standards Control Organisation(CDSCO) (Directorate General of Health Services) and Ministry of Health & Family Welfare (Medical Device and Diagnostic Division)," Zydus Cadila said in a regulatory filing.


    Zydus and SIFI look forward to bring such innovations to India and to the entire South Asia region in order to empower surgeons with advanced technology and consequently better the quality of vision and life of patients, the company added.


    These surgical devices represent the most advanced solution for cataract refractive surgery and the correction of astigmatism (a condition where the cornea is irregularly shaped) and presbyopia (natural loss of near focusing ability that occurs with age).


    'Refractive cataract' is nowadays at the frontier of cataract surgery as it combines clouded lens removal
    to the simultaneous correction of refractive errors such as myopia, hypermetropia, astigmatism and
    presbyopia, in order to free the patient from wearing glasses following the surgery.


    Also Read: Zydus Cadila gets final USFDA nod for Leflunomide tablets to treat arthritis


    The highly advanced IOLs for this purpose are the EDOF (Extended Depth of Focus) lenses that present an optical plate with a continuous series of focuses, able to ensure a continuum correction from far to near in case of presbyopia and in case of astigmatism to provide compensation of the corneal abnormal curvature.







    Cadila Healthcare Ltd is headquartered at Ahmedabad in Gujarat state of western India. The company is one of the leading pharmaceutical companies in India. It is a manufactures, discovers, develops, and markets a broad range of healthcare therapies. While SIFI is an Italian ophthalmic company, focused on eye care since 1935.


    SIFI designs, manufactures and markets innovative pharmaceutical speciality products, nutraceuticals, surgical and medical devices. Headquartered in Catania, Sicily, SIFI operates directly in Italy, France, Spain, Romania, Turkey and Mexico with a staff of more than 400 people worldwide.


    Since June 2015, SIFI is backed by the private equity 21 Invest to support the company's international expansion and portfolio development strategy.


    Also Read: Zydus Cadila gets USFDA nod for Phentermine Hydrochloride orally disintegrating tablets




    astigmatismCadilaCadila Healthcarecataract surgeryCDSCOgovt of indiaIntraocular LensesItalymedical deviceMinistry of Health and Family Welfarepharmapharma newspharma news indiaRefractive cataractRefractive SurgerySIFIsifigroup.comwwwZydus Cadila
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok